Merck & Company Inc (NYSE:MRK) — Market Cap & Net Worth

$284.45 Billion USD  · Rank #61

Market Cap & Net Worth: Merck & Company Inc (MRK)

Merck & Company Inc (NYSE:MRK) has a market capitalization of $284.45 Billion ($284.45 Billion) as of June 18, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #61 globally and #41 in its home market, demonstrating a -3.64% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Merck & Company Inc's stock price $115.17 by its total outstanding shares 2469824415 (2.47 Billion). Review Merck & Company Inc balance sheet liabilities to assess the company's total debt and financial obligations.

Merck & Company Inc Market Cap History: 2015 to 2026

Merck & Company Inc's market capitalization history from 2015 to 2026. Data shows growth from $95.59 Billion to $284.45 Billion (11.14% CAGR).

Index Memberships

Merck & Company Inc is a constituent of 6 market indices:

Index Total Market Cap Weight (%) Rank by Market Cap
Dow Jones Composite Average
DJA
$17.10 Trillion 1.66% #16 of 65
DJC: Dow Jones-UBS Commodity Index
DJC
$23.91 Trillion 0.79% #15 of 65
Dow Jones Industrial Average
DJI
$22.13 Trillion 1.20% #15 of 30
ARCA Pharmaceutical
DRG
$3.26 Trillion 8.72% #4 of 24
S&P 500 Index
GSPC
$62.23 Trillion 0.44% #37 of 503
S&P 100
OEX
$44.56 Trillion 0.63% #34 of 101

Weight: Merck & Company Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Merck & Company Inc Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Merck & Company Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

4.00x

Merck & Company Inc's market cap is 4.00 times its annual revenue

Industry average: 1.27x Higher than industry average

Latest Price to Earnings (P/E) Ratio

14.24x

Merck & Company Inc's market cap is 14.24 times its annual earnings

Industry average: 37.14x Lower than industry average

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2016 $109.98 Billion $39.81 Billion $3.92 Billion 2.76x 28.06x
2017 $108.34 Billion $40.12 Billion $2.39 Billion 2.70x 45.26x
2018 $151.63 Billion $42.29 Billion $6.22 Billion 3.59x 24.38x
2019 $185.39 Billion $39.12 Billion $9.84 Billion 4.74x 18.84x
2020 $172.03 Billion $41.52 Billion $7.07 Billion 4.14x 24.34x
2021 $175.05 Billion $48.70 Billion $13.05 Billion 3.59x 13.41x
2022 $261.56 Billion $59.28 Billion $14.52 Billion 4.41x 18.02x
2023 $264.20 Billion $60.12 Billion $365.00 Million 4.39x 723.85x
2024 $245.70 Billion $64.17 Billion $17.12 Billion 3.83x 14.35x
2025 $259.97 Billion $64.93 Billion $18.25 Billion 4.00x 14.24x

Competitor Companies of MRK by Market Capitalization

Companies near Merck & Company Inc in the global market cap rankings as of June 18, 2026.

Key companies related to Merck & Company Inc by market ranking:

  • Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $936.50 Billion USD.
  • Eli Lilly and Company (SA:LILY34): Ranked #17 globally with a market cap of $853.51 Billion USD ( R$4.35 Trillion BRL).
  • Johnson & Johnson (NYSE:JNJ): Ranked #26 globally with a market cap of $566.62 Billion USD.
  • AbbVie Inc (NYSE:ABBV): Ranked #42 globally with a market cap of $356.49 Billion USD.
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#15 Eli Lilly and Company NYSE:LLY $936.50 Billion $1122.50
#17 Eli Lilly and Company SA:LILY34 $853.51 Billion R$153.70
#26 Johnson & Johnson NYSE:JNJ $566.62 Billion $235.18
#42 AbbVie Inc NYSE:ABBV $356.49 Billion $222.47

Merck & Company Inc Historical Marketcap From 2015 to 2026

Between 2015 and today, Merck & Company Inc's market cap moved from $95.59 Billion to $ 284.45 Billion, with a yearly change of 11.14%.

Year Market Cap Change (%)
2026 $284.45 Billion +9.41%
2025 $259.97 Billion +5.81%
2024 $245.70 Billion -7.00%
2023 $264.20 Billion +1.01%
2022 $261.56 Billion +49.42%
2021 $175.05 Billion +1.75%
2020 $172.03 Billion -7.21%
2019 $185.39 Billion +22.27%
2018 $151.63 Billion +39.95%
2017 $108.34 Billion -1.49%
2016 $109.98 Billion +15.05%
2015 $95.59 Billion --

End of Day Market Cap According to Different Sources

On Jun 17th, 2026 the market cap of Merck & Company Inc was reported to be:

Source Market Cap
Yahoo Finance $284.45 Billion USD
MoneyControl $284.45 Billion USD
MarketWatch $284.45 Billion USD
marketcap.company $284.45 Billion USD
Reuters $284.45 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Merck & Company Inc

NYSE:MRK USA Drug Manufacturers - General
Market Cap
$284.45 Billion
Market Cap Rank
#61 Global
#41 in USA
Share Price
$115.17
Change (1 day)
+0.23%
52-Week Range
$77.60 - $123.93
All Time High
$132.08
About

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, a… Read more